Form S-1
You reference that your platform leverages artificial intelligence, as well as proprietary, advanced algorithms to automate payment-related workflow tasks. Please clarify what you mean by artificial intelligence and explain how it is used in your platform and differs from simple algorithmic code that automates processes in your platform.Rest of the question
In addition, clarify whether your platform utilizes third-party artificial intelligence products or internally developed artificial intelligence processes.
No reply letter found.
Please clarify what you mean by the “flywheel effect” on page 2 and how it relates to your use and capture of data as part of your AI-related systems.
No reply letter found.
We note that the Institutional Investors have certain corporate governance rights if they collectively own 40% of more of the voting power of the total outstanding common stock, such as a lower voting threshold to change your articles or bylaws. Please briefly disclose these rights in the summary.
No reply letter found.
Please provide the basis for your belief that your total addressable market is $15 billion and why you believe it will grow on a compounded annual basis of 5%. Clarify how you calculated these figures.
No reply letter found.
We note your disclosure that “we estimate that our TAM with respect to our current software solution set, is approximately $15 billion today....” Please clarify if this means your market healthcare payment system providers and software-related products and services, or if it is a narrower term meaning a subset of the healthcare payment systems that only have the functions that you currently offer.Rest of the question
If you are referring to a broader market of healthcare-related software beyond payments, provide a more complete description of the market you are referencing.
No reply letter found.
Please clarify how you determined your market share was between 3% and 7% for hospitals and ambulatory practices, respectively, and define the market these market share percentages measure.
No reply letter found.
On page 33 of this risk factor, you reference that your AI platform and data it uses may subject you to additional risks under HIPPA and other health privacy laws. Please clarify whether are referring specifically to the use of AI in the operation of your platform and whether such use may expose you to risks of non-compliance with such health privacy laws.Rest of the question
For example, whether the AI functionality may cause your controls and procedures related to privacy protection to be avoided or overwritten without proper authorization or oversight. Restrictive covenants in the agreements governing our Credit Facilities may restrict our ability to pursue our business strategies, page 39
No reply letter found.
Please provide more detail regarding the restrictive covenants in your existing Credit Facilities and how they may limit your current business operations, including, for example, acquiring other companies, engaging in new lines of business, entering into transactions with affiliates, and transfer or disposal of assets.Rest of the question
You should specify the existing restrictions and explain how it limits your ability to do certain activities and transactions. Management’s discussion and analysis of financial condition and results of operations Results of operations for the six months ended June 30, 2023 and 2022, page 60
No reply letter found.
For revenue, cost of revenue, and other line items where there is a material changes from period-to-period, please expand your discussion to describe the underlying reasons for the material changes in both quantitative and qualitative terms. If more than one factor contributed to the change, quantify each factor. We refer to guidance in Item 303 of Regulation S-K.
No reply letter found.
You state on pages 58 and 62 that increases in revenue were driven by expansion of existing and new clients. Please disclose statistical data regarding client numbers for each period presented in your key performance metrics or tell us why such a metric is not provided. We refer to guidance in Item 303(a) of Regulation S-K.
No reply letter found.
You state that you believe your "existing unrestricted cash on hand, expected future cash flows from operations, and additional borrowings will provide sufficient resources to fund our operating requirements, as well as future capital expenditures, debt service requirements, and investments in future growth for at least the next twelve months." Please expand your discussion to also analyze your ability to generateRest of the question
and obtain adequate amounts of cash to meet your requirements in the long-term (i.e., beyond the next 12 months). We refer to guidance in Item 303(b)(1) of Regulation S-K.
No reply letter found.
Please expand your discussion of goodwill impairment to explain how goodwill was tested, significant judgements and assumptions made during testing, and the sensitivity of goodwill to future impairment.
No reply letter found.
On pages 3 and 16, you reference that your platform is integrated with over 200 vendors, including ERP, EHR and PM systems. You further indicate that you have entered strategic relationships with channel partners to sell your solutions. Please described these relationships in more detail and clarify if you are materially dependent on any of these ERP, EHR, PM or strategic partners or types of strategic partners.Rest of the question
For example, clarify, if true, whether you are dependent on a small number of ERPs to sell your platform through their systems for your larger enterprise clients or clients where you generate more than $100,000 in revenue per client.
No reply letter found.
On pages 21-22, you reference that you are reliant on third-party vendors for critical services such as clearinghouse systems, payment processing services, software development, and eligibility verification. Please clarify whether any of these relationships are material, and if so, please describe the respective agreements.Rest of the question
Further, please expand your Business section to discuss how these critical services operate through your platform. For example, your Research and Development discussion appears to imply that the development and improvement of your platform is handled in-house. If you are reliant on outside software developers for this work, please clarify so.
No reply letter found.
We note that billing errors and mistakes related to billing may have a significant effect on your clients, the end users, and your business. Please clarify how your system can avoid or reduce billing errors.
No reply letter found.
We note that you provide several examples of how your clients use your platform to address their payment and business challenges, which include references to various statistics and financial measures. When using such information, please reference the periods, timeframes, and/or dates being measured to provide context of what is being measured.
No reply letter found.
On page 15, you briefly describe your client agreements are typically are 2-3 years in duration, renew automatically in 1-year increments, and allow the client to terminate the agreement early. Please clarify whether your typical client agreement allows for early termination without significant penalty and the ease, or lack thereof, to switch to a competitor from a financial or technological point of view.Rest of the question
Further, clarify whether management calculates and evaluates renewal rates as part of this oversight and management of your business and if they are a key metric.
No reply letter found.
Please provide more details of your competition and your competitive environment. We note that you indicate that your market share is less than 7% of the market. Yet you believe that no competitor matches the breadth and depth of your solutions. Clarify, for example, if the market is highly fragmented and mostly consists of similarly sized or smaller healthcare payments focused companies.Rest of the question
It is unclear whether the ERP, HER, PM or other strategic partners also provide potentially competing payments or payments workflow-related solutions.
No reply letter found.
We note that several of your directors are affiliated with principal stockholders, namely your Institutional Investors. Please clarify if these directors were appointed through any nomination or appointment right through any agreement.
No reply letter found.
Please explain further what you mean by the “highest level of support” that will be provided to EQT, CPPIB, and Bain director nominees. For example, clarify whether each of EQT, CPPIB, and Bain may nominate a director and whether the parties to the shareholders agreement are obligated to vote their shares to elect those nominees.Rest of the question
Further, clarify whether this provision terminates if EQT, CPPIB, and Bain’s collective beneficial ownership falls below a certain voting threshold similar to the provision that would eliminate the classified board structure should they collectively own less than 15% of the voting power of the total outstanding shares entitled to vote in director elections. Principal stockholders, page 110
No reply letter found.
Please disclose the natural person(s) that hold investment and/or voting power over the shares held by the Institutional Investors, other than the funds affiliated with EQT Investor.
No reply letter found.
You indicate in this section there is a single class of common stock, but you refer to issued and outstanding Class A Common Stock with no voting rights on page F-28. Please clarify. Notes to Consolidated Financial Statements 16. Stock-based compensation, page F-28
No reply letter found.
We note your statement on page F-29 that, "At December 31, 2022, we did not believe the vesting of performance condition options criteria was probable and, therefore, no stockbased compensation has been recorded." That statement appears to contradict disclosure regarding stock-based compensation expense recorded on page F-28. Please clarify your disclosure to distinguish between various types of stock options.
No reply letter found.
For performance based stock options, please disclose the specific performance conditions and the amount of expense you will incur once the vesting of performance criteria becomes probable.
No reply letter found.
Please provide a summary of stock options granted since January 1, 2022. Provide the date and amount of each stock option granted along with estimated fair value of the underlying shares of common stock. Reconcile and explain the differences between the fair values determined on each grant date including the difference between the most recent grant date fair value and the midpoint of your offering range.Rest of the question
This reconciliation should describe significant intervening events within the company and changes in assumptions with the valuation methodologies employed that explain the changes in fair value of your common stock up to the filing of the registration statement. Continue to provide us with updates to the above analysis for all equity related transactions through the effectiveness date of the registration statement.
No reply letter found.
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
No reply letter found.
We note your response to prior comment 4 regarding your reference to a third-party commissioned report providing support for your TAM, growth rate projections and market share. Please identify the author and/or creator of this report, the title of the report, and the date the report was issued. Further, please provide an appropriate consent pursuant to Rule 436.Rest of the question
Clarify if this report is the same one referenced on page 6 for your client satisfaction statistics. If not, please provide similar disclosures for this report as well. Management’s discussion and analysis of financial condition and results of operations Key performance metrics and non-GAAP financial measures, page 66
Company acknowledges the Staff’s comment and advises the Staff that the third-party report, titled “WaystarRead in the reply
Strategy”, was initially commissioned by the Company in 2019 and prepared by a very large and internationally recognized management consulting firm. Since the initial report in 2019, the Company has commissioned periodic updates to the report from time to time, most recently in February 2023. The Company notes that the terms of use of the third-party report do not permit the Company to name the author in any publication, including any filings made with the Commission.Rest of the answer
The third-party report was commissioned by the Company in the ordinary course of business and was not prepared in contemplation of an offering or for purposes of the
Registration Statement. The Company respectfully submits that the consent requirements of Section 7 and Rule 436 are generally directed at circumstances in which an issuer has engaged a third-party expert or counsel to prepare a valuation, opinion or other report specifically for use in connection with a registration statement. Therefore, the Company believes that the author of the third-party report is not required to be named as an “expert” in the Registration Statement.
Company respectfully notes that it has included a description of the methodology and underlying assumptions for calculating its TAM, growth rate projections and market share on pages 4, 5, 81, and 82 of the Registration Statement. The Company believes such methodology and assumptions to be reasonable, which are consistent with the methodology and assumptions used in the third-party report.
addition, the Company notes that the third-party report with respect to its industry and market data is different from the third-party survey referenced on pages 6 and 84 relating to the Company’s client satisfaction statistics. The Company respectfully submits that the third-party consultant which administered and conducted the client satisfaction survey is not among the class of persons subject to Section 7 and Rule 436 as “experts”. The Company has referred to the third-party survey solely to indicate that such survey was not conducted in-house, and such references were not intended to infer that any information was “expertized” by any third party. The Company has not expressly identified such third party as an expert and believes that the company administering the survey should not be considered an “expert” within the meaning of Rule 436 and the federal securities laws.
We note your response to comment 10. However your current disclosure states, "The number of clients from whom we generate over $100,000 of revenue has grown from 733 in the twelve months ended March 31, 2021 to 1,023 in the twelve months ended June 30, 2023." Please include a table in Key Performance Metrics that shows the number of clients from whom you generate over $100,000 in revenue for each period presented.Rest of the question
Showing this statistical measure for each period presented will allow readers to analyze your growth rates for each period.
The Company has revised its disclosure on pages 68 and 69 in response to the Staff’s comment.Read in the reply
We note your response to comment 12 and the new disclosure added to page 73. You state that prior assessments have indicated the fair value exceeds the carrying value for the reporting units with reasonable headroom. Please disclose when the prior assessments were performed. Disclose any other indicators considered that supported your qualitative assertion.Rest of the question
Also, tell us your reason for performing a quantitative assessment every fourth year and how that aligns with accounting guidance. Notes to consolidated financial statements 2. Summary of significant accounting policies
The Company has revised its disclosure on page 76 in response to the Staff’s comment.Read in the reply
ASC Topic 350-20-35A states that an entity may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount, including goodwill.Rest of the answer
In addition,
ASC Topic 350-20-35A states that an entity has an unconditional option to bypass the qualitative assessment described in the preceding paragraph for any reporting unit in any period and proceed directly to performing the first step of the goodwill impairment test. Our policy is to perform a qualitative assessment to evaluate whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, including goodwill. At least every four years, unless circumstances warrant a more frequent evaluation, we elect the option under ASC Topic 350-20-35A to perform a quantitative assessment in order to better understand the quantitative difference between our reporting unit’s fair value and its carrying amount.
Notes to consolidated financial statements
2. Summary of significant accounting policies
On page 62 you disclose that the overall increase in revenue was the result of a $25.0 million increase from provider solutions and a $17.3 million increase from patient payments. In this regard, please expand your revenue recognition disclosure to explain why patients payments are included in revenue. Disclose who is your customer. Refer to your basis in accounting literature.
has revised its disclosure on pages 61, 63, 65, F-10, and F-38 in response to the Staff’s comment.Read in the reply
For further clarification, the Company advises the Staff that “patient payments” refers to products that assist healthcare providers in collecting payments from patients, and does not refer to payments remitted from patients to healthcare providers, which are not recorded in the Company’s revenue. The Company does not contract with patients nor does the Company control the services provided to the patients by healthcare providers.Rest of the answer
Patient payments solutions are provided to the Company’s customers in the form of subscription or volume-based services as described on page F-10.
We note that you provide your revenue for the fiscal year ended December 31, 2022 in your graphics page in the forepart of your prospectus. Please include your net losses for the same period with equal prominence. Further, please clarify the period or dates yours number of Clients and Annual Healthcare Payment Transaction statistics were measured.
has revised its disclosure on its graphics page in response to the Staff’s comment.Read in the reply
Your graphics page refers to you having "Industry Leading Technology at Scale." Please clarify the basis for this statement either on your graphics page or in your prospectus summary.
Company has revised its disclosure on pages 5 and 83 in response to the Staff’s comment.Read in the reply
We note based on your disclosure on pages 115 to 122, that you expect to award IPO equity awards and other new compensation awards in connection with this offering. Please disclose the expected future expense that will result once this offering is effective. Disclose when that expense is expected to affect your results of operations.
Company has revised its disclosure on pages 61 and 62 in response to the Staff’s comment. The Company advises the Staff that the dollar amounts and the numbers of options and restricted stock units in the revised disclosure will be added once the midpoint of the estimated price range is determined.Read in the reply
Please clarify your subscription and volume revenue discussion by focusing on your provider and patient payment solution categories. In regards to subscription revenue, for example, detail and quantify the underlying factors that drove the growth in provider solution sales, such as the increase in new customers.Rest of the question
Similarly, disclose, discuss and quantify the increase in volume revenue from both provider and patient payment solution sales.
Company has revised its disclosure on pages 64, 65 and 66 in response to the Staff’s comment.Read in the reply
Also, discuss how changes in your provider and patient payment solution sales categories affect cost of revenues and your margins.
Company has revised its disclosure on pages 64 and 66 in response to the Staff’s comment.Read in the reply
We note your current amendment eliminated the following phrase from the cost of revenue discussion when comparing December 31, 2021 to December 31, 2022: "The higher increase in cost of revenue as compared to the increase in revenues reflects the Patientco acquisition and associated higher patient payment solution cost of revenues." Please tell us, and revise to discuss, if the Patientco acquisition and associatedRest of the question
higher patient payment costs had an effect on margins. Also, tell us if management reviews margins as they relate to the patient payment and provider solutions product offerings.
The Company has restored the previously deleted sentence describing the decrease in margins for the comparative period as a result of the Patientco acquisition. See page 66.Read in the reply
In addition, please note that on page 61 the Company discloses that “acquired solutions primarily generate volume-based revenue, with a higher cost of revenue relative to the cost of revenue for other Waystar solutions.” The Company also confirms that management, including its CEO as chief operating decision maker, does not review separate patient payment and provider solutions margins for planning purposes or evaluatingRest of the answer
financial performance.
Please expand your discussion here and/or in your related party disclosures to clarify all material corporate governance rights that are provided to your principal stockholders EQT, CPPIB, and Bain Capital. We note, for example, that one or more of these stockholders will have board observer rights and nomination rights for subsidiary boards or committees under certain circumstances.
The Company has revised its disclosure on pages 104 and 123 in response to the Staff’s comment.Read in the reply
We note your response to our prior comment one and your restored disclosure. Please expand your results of operations discussion for nine months ended December 31, 2023, to discuss and analyze how the acquired solutions with relatively higher cost of revenues impacted the change in total cost of revenue as a percentage of reported revenue.Rest of the question
Also, since your recent acquisitions “primarily generate volume-based revenue, with a higher cost of revenue relative to the cost of revenue for other Waystar solutions,” disclose if this is a known trend that is reasonably likely to have a favorable or unfavorable impact on your cost of revenues and income from continuing operations. We refer to guidance in Item 303(b)(2)(ii) of Regulation S-K.
The Company advises the Staff that there was only an approximate 40 basis point difference as a percentage of revenues for the cost of revenue (exclusive of depreciation and amortization) for the nine months ended September 30, 2023 (31.2%) compared to the nine months ended September 30, 2022 (30.8%).Read in the reply
As such, the Company does not consider the difference to be material and respectfully submits that, in accordance with the guidance provided in Item 303(b)(2)(ii) of Regulation S-K, such difference is not required to be further discussed in the results of operations discussion for the nineRest of the answer
months ended September 30, 2023 and 2022. The Company notes that the percentage for the year ended December 31, 2022 was
30.5%, which is comparable to the percentages for both the nine months ended September 30, 2023 and 2022 periods. These percentages fully reflect the higher cost of revenue for the volume-based revenue generated by the acquired solutions, and the Company does not expect any further material impact to its cost of revenues or income from continuing operations for future periods as a result of such acquisitions.
The Company further advises the Staff that it has revised the disclosure on page 61 to state that the impact of the higher cost of revenue associated with the additional volume-based revenue generated by the specified acquisitions is not expected to materially change post-acquisition.
Regarding your segments and response to our prior comment one: • Tell us what financial information is provided to your company’s chief operating decision maker (i.e., CODM) and the frequency in which it is provided. • Tell us the title and describe the role of each of the individuals who reports to your CODM.Rest of the question
• Tell us how often the CODM meets with each of his direct reports, the nature of any financial information the CODM receives or discusses with his direct reports when they meet, and the other participants at those meetings.
The Company advises the Staff of the following:Read in the reply
· The
Company compiles and provides a monthly reporting package to its chief operating decision maker (the “CODM”) to facilitate the review of its operational performance, make decisions regarding resource allocation as well as for approval of budgets and forecasts.
Financial results and metrics are presented, reviewed and evaluated for the Company as a whole, at the consolidated level.Rest of the answer
The reporting package includes actual, plan, prior year information and variance on P&L, balance sheet and cash flow line items, client operational information, bookings, Adjusted EBITDA, selective financial ratios, customer analytics, revenue retention and client operations information, in each case, at a consolidated level. Although supplemental disaggregated revenue and customer information is also included in such monthly reporting package, that information is not sufficient to evaluate profitability at a disaggregated level and no other discrete financial information (including operating expense metrics or any other profitability metric on a disaggregated basis) is provided. In addition, the key profitability metric the CODM evaluates to make resource allocation decisions is Adjusted
EBITDA, which is only available on a consolidated level. Due to the fact that the CODM only uses consolidated operating results and other consolidated financial information in the allocation of resources and assessment of Company performance, the Company is of the view that it only has one operating segment and thus has only one reportable segment.
CODM is the Company’s CEO. He is the highest-ranking member of executive management within the Company and has seven direct C-suite members reporting to him, as listed below.
Together with the direct reports mentioned below, this comprises the executive leadership team (the “ELT”).
o Chief
Technology Officer – Head of technology function
Transformation Officer – Head of client experience and business operations functions
Business Officer – Head of sales, M&A and strategy functions
Legal & Administrative Officer – Head of legal function
Marketing Officer – Head of marketing function
Financial Officer – Head of finance and financial reporting functions
People Offer – Head of human resources function
· This executive leadership team meets on weekly basis at which each functional area leader provides an update regarding applicable items included in the monthly reporting package discussed above and other pertinent items for the group. The Company’s ultimate decision-making authority rests with the CEO who is responsible for operating the business and guides the
Company’s strategic direction, including allocating resources to accomplish organizational initiatives, entering into significant contracts, acquisitions and divestitures, significant capital expenditures, key personnel staffing, and approving operating budgets. The members of the ELT, aside from the CODM, are functional leaders over their particular areas of expertise, rather than being directly accountable for the operating activities, financial results, forecasts, or plans for a type of customer, product or service.
In addition, the Company advises the Staff that it has no business units or product segments and no regional or general managers. The Company has centralized corporate functions, such as shared sales and marketing and research and development functions, which serve the consolidated business and are not organized by region, product line or otherwise. Further, the Company’s senior leadership compensation structure is based on consolidated performance metrics, and not on any specific product line or functional area they support.
The Company operates under a single operating strategy, which is to provide healthcare organizations with mission-critical cloud software that simplifies healthcare payments.
The Company believes this requires it to provide both patient payments as well as provider solutions in order to provide a single comprehensive and holistic healthcare payment platform to its clients. The Company’s patient payments and provider solutions are part of a single business and are interdependent, and, as a result, resource allocation decisions made by the CODM generally impact the success of the overall business and do not have a targeted impact on any individual product or solution. For this reason, the Company does not allocate shared operating expenses to individual products or solutions for management reporting purposes, and resource allocation decisions are based on consolidated operating results. This is evidenced by the fact that the Company’s financial planning and accounting systems are not currently designed to budget, record transactions, or otherwise allocate shared costs for the purpose of reporting operating margin at the product or solution level or at any other level of disaggregation.
although it provides certain information in Amendment No. 3 regarding third-party costs for patient payment solutions as compared to third-party costs for provider solutions, such information does not include any internal cost allocations and therefore is not sufficient to evaluate profitability at a disaggregated level and is not reviewed by the CODM. In addition, such direct costs are exclusive of significant costs included in cost of revenue and therefore do not allow the Company to calculate gross margins by product line. Such direct costs also do not include other operating expenses and do not represent discrete financial information necessary to effectively manage the business. As noted above, the CODM and the Company do not review or evaluate cost of revenues or margins for any particular product type and only revenue and customer information, as well as third-party direct costs, are available by product lines.
Based on the foregoing, the Company maintains it has one operating segment because the CODM assesses financial performance and makes decisions with regard to resource allocation at the total Company level based on the Company’s overall financial results of operations. The Company’s products are delivered to customers via a single Waystar software platform and therefore internal operating costs related to the platform are not allocable by product offering, nor is there a sufficient basis to do so for purpose of allocating capital and resources. The Company believes providing financial information by a single operating segment is consistent with management’s organization of the Company to make operating decisions and assess performance, and believes that reporting its product lines as more than one operating segment would not add to stakeholders’ understanding of the Company.
We note based on your disclosure on pages 115 to 122, that you expect to award IPO equity awards and other new compensation awards in connection with this offering. Please disclose the expected future expense that will result once this offering is effective. Disclose when that expense is expected to affect your results of operations.
The Company confirms to the Staff that it will disclose the initial stock-based compensation expense relating to the awards to be granted in connection with the IPO on page 61 of the Registration Statement and notes that page 62 of the Registration Statement discloses that stock-based compensation expense will be reflected in the Company’s results of operations from the closing date of the IPO through the applicable vesting periods of such awards.Read in the reply
You illustrate the growth in the number of clients from whom you generate over $100,000 of revenue by disclosing the number of such clients in the twelve months ended March 31, 2021 compared to the year ended December 31, 2023. To provide further context, please explain the relevance of the twelve months ended March 31, 2021, and disclose the number of such clients for the years ended December 31, 2021 and 2022.Rest of the question
Principal stockholders, page 125
The Company has revised its disclosure on pages 1, 61, 70, 78 and 88 in response to theRead in the reply
Staff’s comment.
Please clarify why you have presented the columns comprising "Shares of our common stock to be sold in the offering." If there will be selling shareholders, please revise your cover page and elsewhere to disclose that there will be a selling shareholder component of the offering. If there will not be selling shareholders, then remove these columns.Rest of the question
You may disclose in the introductory paragraphs or a footnote to the table how the number of outstanding shares will change based upon the shares being offered and if the underwriters' over-allotment option is exercised.
Company has revised its disclosure on page 128 in response to the Staff’s comment.Read in the reply
Please provide more detail regarding the $10.4 million of costs incurred during the three months ended March 31, 2024 related to amended debt agreements and tell us why you believe they are not a normal, recurring, cash operating expense. Refer to the Division's Non-GAAP Financial Measures Compliance and Disclosure Interpretations, Question 100.01.Rest of the question
We note in your disclosure on page F-48 that in connection with the February 2024 First Lien Refinancing, you recorded $10.3 million in third party fees.
The Company respectfully acknowledges the Staff’s comment. As stated in Question 100.01, “When evaluating what is a normal, operating expense, the staff considers the nature and effect of the non-GAAP adjustment and how it relates to the company’s operations, revenue generating activities, business strategy, industry and regulatory environment.” The costs related to the refinancing of the Company’s debt agreements are related to third party fees incurred as part of the February 2024 First Lien Refinancing described on page F-47, including legal fees, rating agency fees and arranger feesRead in the replyRest of the answer
incurred as part of a debt modification related to the February 2024 First Lien
Refinancing described on page F-47 and legal fees associated with the February 2024 Second Lien Paydown described on page F-47.
Third party fees associated with refinancings and unscheduled principal payoffs are incurred infrequently as they are costs incurred only in connection with opportunistic refinancings and repricings of the Company’s credit facilities. The Company does not view these as normal, recurring, cash operating expenses as these costs do not relate to the company’s operations, business activities, or strategies, are not incurred in connection with revenue generating activities, and are not necessary to operate the company’s business.
Further, the Company does not describe these costs as non-recurring, infrequent, or unusual. Although these costs may recur between periods, the Company believes it is appropriate to exclude these costs from the definition of Adjusted EBITDA, as may be permitted as set forth in the Division’s Non-GAAP Financial
Measures Compliance and Disclosure Interpretations, Question 102.03, which states that “[t]he fact that a registrant cannot describe a charge or gain as non-recurring, infrequent or unusual, however, does not mean that the registrant cannot adjust for that charge or gain” so long as the exclusion is in accordance with Regulation G and other requirements of Item 10(e) of Regulation S-K.
In addition, the Company has revised its disclosure on page 65 to clarify the components of the $10.4 million expense related to the refinancing.
Also in this review: company letter, May 21, 2024, company letter, Jun 4, 2024